We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Excess MicroRNA from Chromosome 21 Causes Down Syndrome Mental Impairment

By LabMedica International staff writers
Posted on 10 Apr 2013
Some of the neurological impairments typical of Down syndrome (DS) are caused by abnormally high levels of a microRNA (miRNA) that inhibits the manufacture of the protein SNX27 (sorting nexin 27).

DS, also known as trisomy 21, is a chromosomal condition caused by the presence of all or part of a third copy of chromosome 21. More...
It is the most common chromosome abnormality in humans and is typically associated with a delay in cognitive ability and physical growth and a particular set of facial characteristics.

SNX27 is a member of the sorting nexin family, a diverse group of cytoplasmic and membrane-associated proteins involved in endocytosis of plasma membrane receptors and protein trafficking through these compartments. All members of this protein family contain a phosphoinositide binding domain (PX domain). Mice that lack both genes for production of SNX27 have severe neuronal deficits in the hippocampus and cortex while mice with only one SBX27 gene have grossly normal neuroanatomy but have defects in synaptic function, learning, and memory.

Investigators at the Sanford-Burnham Medical Research Institute (La Jolla, CA, USA) analyzed brain tissue from subjects with DS and confirmed that they contained significantly lower levels of SNX27 than was found in normal individuals.

Studies carried out on a DS mouse model revealed that the activity of the SNX27 gene was being regulated by the microRNA miR-155, which is produced on chromosome 21. By having an extra copy of this chromosome an individual with DS generates excess miR-155, which results in abnormally low levels of SNX27 and mental defects.

Additional results published in the March 24, 2013, online edition of the journal Nature Medicine showed that a viral vector containing additional genes for SNX27 production could be inserted into the brains of the DS mice, and that return of SNX27 levels to normal corrected the animals' synaptic and cognitive deficits.

“In the brain, SNX27 keeps certain receptors on the cell surface - receptors that are necessary for neurons to fire properly,” said senior author Dr. Huaxi Xu, professor of neuroscience at the Sanford-Burnham Medical Research Institute. “So, in Down syndrome, we believe lack of SNX27 is at least partly to blame for developmental and cognitive defects.”

Related Links:

Sanford-Burnham Medical Research



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.